Clinical Trial

Endothelin-1 Receptor Blockade in Resistant Hypertension

Study acronym: ENDOTHELIN-2
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The management of patients with resistant arterial hypertension, who are characterized by a very high cardiovascular risk, remains a major therapeutic issue. The use of endothelin-1 (ET-1) receptor antagonists, in addition to lowering blood pressure, may also improve endothelial function in these patients. The objective of this study is to assess the vascular impact of an ET-1 receptor antagonist on vascular function and systemic and central hemodynamics in patients with resistant arterial hypertension and ensure their good renal tolerance.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-05-13.
Status change: Not Yet Recruiting → Recruiting 2026-02-12
Trial Details
NCT Number NCT04388124
Lead Sponsor University Hospital, Rouen
Conditions Resistant Hypertension
Enrollment 24 participants
Start Date 2021-10-20
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-17